News Category
VERAXA Biotech's appointment of Dr. Christoph Erkel as Chief Scientific Officer signals a strategic push to advance its BiTAC® T-cell engager platform...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, moves toward a Phase 2 trial in multiple sclerosis after FDA clearance of its IND appli...
Quantum BioPharma receives FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and potentially ...
Quantum BioPharma's Lucid-MS, the first drug designed to protect and rebuild myelin, receives FDA clearance for a Phase 2 trial, offering new hope for...
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, a novel PNKP inhibitor with dual selectivity mechanisms, and its planned fir...
Quantum BioPharma's FDA clearance of its IND for Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, enables a Phase 2 trial in multiple sclerosis...
The article highlights the often-overlooked crisis in UTI diagnosis, emphasizing the need for improved diagnostic tools and the potential role of comp...
Silo Pharma's participation in the IPAC-RS forum underscores its commitment to advancing SPC-15, a nose-to-brain drug delivery system for PTSD, backed...
Quantum BioPharma's Lucid-MS, a novel myelin repair candidate for multiple sclerosis, received FDA clearance for Phase 2 trials, marking a significant...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective multiple sclerosis drug candidate, has received FDA clearance to begin a Phase 2 clin...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's readiness to contribute to a diversified vaccine supply f...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO signals a strategic move to bolster its capital strategy and advance...
Scinai Immunotherapeutics refocuses its R&D portfolio after terminating a license agreement, prioritizing its NanoAb platform and CDMO business to enh...
Onco-Innovations is advancing its oncology pipeline by securing manufacturing capabilities, IND-enabling activities, partnerships, and funding, markin...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class remyelinating agent, marks a pivotal step toward potentially treat...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Ocumetics Technology Corp. has initiated patient recruitment for Group Two of its clinical study, moving beyond safety to evaluate the vision performa...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a potential breakthrough in MS treatment by targeting myelin repair, not ju...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the DRC, marking a significant step in developing a broad-spectrum an...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of its investigational multiple sclerosis drug Lucid-MS, marking a critical step...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class PAD2 inhibitor targeting demyelination in MS, marks a pivotal...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant step toward a targeted therapy for multiple sclerosis, potentially sh...
Tonix Pharmaceuticals promotes Thomas Englese to Chief Commercial Officer to lead commercial operations for its fibromyalgia treatment TONMYA, signali...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, highlighting the n...
Onco-Innovations reports significant progress in developing ONC010, a PNKP inhibitor for cancer therapy, including high-purity manufacturing and plans...
OS Therapies' participation in the Moody Capital conference comes as the company anticipates key FDA and U.K. regulatory decisions for its lead candid...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, potentia...
The FDA's failure to aggressively enforce regulations allows an illegal online market for the investigational drug retatrutide to thrive, endangering ...
New research from Mass General Brigham suggests that unintentional radiation to the thymus during lung cancer treatment may worsen clinical results, h...
Tonix Pharmaceuticals' participation in the Cantor conference underscores its strategic focus on advancing treatments for CNS disorders and immunology...
NurExone Biologic will showcase its exosome-based therapeutic platform and U.S. expansion plans at a prestigious conference, highlighting its progress...
CNS Pharmaceuticals' Chief Business Officer details the company's strategy to build a pipeline in oncology and neurology through in-licensing and acqu...
Dr. Salman Fazal's third consecutive Castle Connolly Top Doctor honor underscores his leadership in advanced hematologic cancer care and cellular ther...
Quantum BioPharma's Lucid-MS candidate for progressive multiple sclerosis garners a 'Buy' rating and $8 price target from Rodman & Renshaw, underscori...
NanoViricides is advancing its measles treatment NV-387 toward a Phase II trial, leveraging FDA designations and promising animal data, as measles out...
TransCode Therapeutics' preclinical study shows its lead candidate TTX-MC138 improves survival in a breast cancer bone metastasis model, supporting it...
Oragenics provides key updates on its Phase IIa concussion trial, FDA interactions, and NYSE American compliance, underscoring its progress and hurdle...
Experts and a patient advocate highlight the importance of PSMA PET scans in guiding prostate cancer treatment, urging men to ask their doctors about ...
A nurse's battle with metastatic triple-negative breast cancer underscores the significance of innovative antibody-drug conjugates (ADCs) and the need...
An updated expert consensus provides 18 recommendations for diagnosing and managing childhood nocturnal enuresis, lowering the diagnostic threshold an...
A new randomized controlled trial tests whether a school-based plyometric HIIT program can improve muscle-to-fat ratio in children, potentially shifti...
A forthcoming University of Houston study undermines the long-held 'shunting theory' that ECT is safe, showing that most current reaches the brain, pr...
Creative Biolabs updates its in vivo CAR-T development portfolio, offering both viral and non-viral delivery options to support researchers investigat...
Heidelberg Pharma and Huadong Medicine received NMPA approval to test HDP-101 in combination therapies for multiple myeloma, potentially expanding its...
A new study published in Critical Care Medicine reveals that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality and renal r...
Lakewood-Amedex Biotherapeutics, a clinical-stage biotech developing novel antimicrobials, becomes a B2i Digital Featured Company as it prepares a Pha...
Citius Pharmaceuticals' commercial launch of LYMPHIR and promising late-stage pipeline signals a pivotal shift toward revenue generation and multiple ...
